Straits Times Index
3,323.38 +0.18 (+0.01%) S&P 500
5,248.61 -18.34 (-0.35%) Dow
38,115.20 -326.34 (-0.85%) Nasdaq
16,819.62 -100.96 (-0.60%) Bitcoin USD
69,240.98 +1,969.78 (+2.93%) CMC Crypto 200
1,449.33 -6.54 (-0.45%)
AbbVie Inc. (ABBV)
- Zacks
Are Options Traders Betting on a Big Move in AbbVie (ABBV) Stock?
Investors need to pay close attention to AbbVie (ABBV) stock based on the movements in the options market lately.
- Zacks
AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It
AbbVie (ABBV) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
- PR Newswire
AbbVie Showcases Robust Solid Tumor Pipeline at ASCO 2024 with New Data from Its Innovative Antibody-Drug Conjugate (ADC) Platform
AbbVie (NYSE: ABBV) today announced that new data from its innovative antibody-drug conjugate (ADC) platform will be showcased across three oral presentations at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting (May 31 - June 4, 2024). AbbVie's ADCs are designed to target unique protein biomarkers such as c-Met (MET protein) and SEZ6 (seizure-related homolog 6 protein), which are over-expressed across various tumor types. By utilizing these biomarkers as targets, ADCs are
